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Abstract
Objective: Knowing the effectiveness of high doses of 
calcium in preventing preeclampsia.
Methods:  Experimental analytical study with Randomized 
Controlled design Single-blind trial in the form of survival 
analysis (survival analysis) in the period June 2018 - May 
2019 in fetomaternal outpatients clinic in Mohammad 
Hoesin Hospital, Palembang
Results: The mean hemoglobin level at the last visit found 
that the average hemoglobin level between the two groups 
was 12.81 in the high calcium group and 12.61 in the low 
calcium group, while the mean hematocrit level between 
the two groups was 35.17 in the high calcium group and 
34.84 in the low calcium group and the respective calcium 
levels each group is 10.1. In this study, after high calcium 
intervention, no pregnant women with preeclampsia were 
found, whereas in the low-dose calcium intervention group 
it was found that 3 of 17 patients (17.7%) had preeclampsia. 
With the McNemar test it was found that there was no 
difference in the incidence of preeclampsia both after high-
dose calcium and low-dose calcium interventions (p = 
0.250).
Conclusions: High-dose calcium (1.5g - 2g) is effective in 
preventing preeclampsia and there was no difference in 
effectiveness between administration of high-dose calcium 
with low-dose calcium administration to the incidence of 
preeclampsia.
Keywords: high dose calcium, preeclampsia, randomized 
control trial.
Abstrak
Tujuan: Mengetahui efektivitas pemberian kalsium dosis 
tinggi dalam mencegah preeklamsia.
Metode: Penelitian analitik eksperimental dengan desain 
randomized controlled trial single blind dalam bentuk ujian 
alias kesintasan (survival analysis) dalam kurun waktu Juni 
2018 – Mei 2019 di Poliklinik Fetomaternal Rumah Sakit 
Umum Pendidikan Mohammad Hoesin, Palembang
Hasil: Rerata kadar hemoglobin pada kunjungan terakhir 
didapatkan rerata kadar hemoglobin antara kedua 
kelompok adalah 12,81 pada kelompok kalsium tinggi dan 
12,61 pada kelompok kalsium rendah, sedangkan rerata 
kadar hematokrit antara kedua kelompok adalah 35,17 
pada kelompok kalsium tinggi dan 34,84 pada kelompok 
kalsium rendah dan rerata kadar kalsium masing-masing 
kelompok adalah 10,1. Pada penelitian ini setelah intervensi 
kalsium tinggi tidak ditemukan ibu hamil yang mengalami 
preeklamsia, sedangkan pada kelompok intervensi kalsium 
dosis rendah ditemukan 3 dari 17 pasien (17,7%) menderita 
preeklamsia. Dengan uji Mc Nemar didapatkan hasil tidak 
terdapat perbedaan kejadian preeklamsia baik setelah 
intervensi kalsium dosis tinggi maupun kalsium dosis rendah 
(p = 0,250). Hal ini berarti kalsium dosis tinggi dan rendah 
efektif untuk mencegah preeklamsia.
Kesimpulan: Kalsium dosis tinggi (1,5g – 2g) efektif dalam 
mencegah preeklamsia dan tidak ditemukan perbedaan 
efektivitas antara pemberian kalsium dosis tinggi dengan 
pemberian kalsium dosis rendah terhadap kejadian 
preeklamsia.
Kata kunci: kalsium dosis tinggi, preeklamsia, randomized 
control trial.
INTRODUCTION
Preeclampsia is a specifi c multisystem 
disorder in pregnancy characterized by the 
development of hypertension and proteinuria 
after 20 weeks of pregnancy. Preeclampsia is 
a life-threatening disorder that only occurs 
during pregnancy, labour, and the postpartum 
period and is characterized by high blood 
pressure (hypertension) and protein in the urine 
(proteinuria). Preeclampsia is stated to have a 
signifi cant effect on the morbidity and mortality 
of pregnant women and fetuses.1
According to WHO, the average incidence of 
preeclampsia in various countries in 2013 ranged 
from 0.51-38.4%. In developed countries, the 
incidence of preeclampsia ranges from 6-7%. The 
World Health Organization (WHO) estimated that 
there were 303,000 maternal deaths in the world 
in 2015. According to the MDG program, there has 
been a decline of 43% of maternal deaths in 1990. 
The prevalence of death caused by preeclampsia 
in 2000 in the world was 12%. In Indonesia itself 
according to the KIA report of the Directorate of 
Health Development for the Ministry of Health of 
the Republic of Indonesia in 2011, the incidence 
of preeclampsia is around 3.4-8.5%. The number 
of maternal deaths reported was 2,118. The cause 
of maternal death due to preeclampsia is around 
25%. The maternal mortality rate in Indonesia is 
still high compared to ASEAN countries. Based 
on data from the Indonesian Demographic 
and Health Survey (IDHS) in 2012, the Maternal 
Mortality Rate (MMR) in Indonesia amounted 
to 395 per 100,000. The number of maternal 
deaths in 2015 in the city of Palembang, based 
on a report of 12 people from 29,011 live births 
(Profi le of Basic Health Services, 2015). The causes 
were bleeding (41.7%), followed by pulmonary 
embolism (1 case), suspected cardiogenic shock 
(1 case), eclampsia (1 case), suspected TB (1 case), 
hypertension in pregnancy (1 case), and others.2-5
In addition to maternal deaths, preeclampsia 
also affects perinatal delivery, including preterm 
birth, stunted fetal growth or Intra Uterine 
Growth Retardation (IUGR), perinatal death and 
long-term morbidity of cardiovascular disease 
associated with low birth weight (LBW). The 
incidence of hypertension in pregnant women is 
caused by various causes including nutrients or 
nutrients contained in food. Calcium defi ciency 
contributes to the occurrence of high blood 
pressure during pregnancy. WHO (2013) states 
that the administration of calcium to pregnant 
women is one way that can be used to prevent 
preeclampsia. Various studies have shown that 
high-dose calcium supplementation during 
pregnancy has a benefi cial effect to reduce 
the risk of hypertension due to pregnancy 
or preeclampsia.6,7 Therefore, researchers are 
interested in further analyzing the role of 
high-dose calcium to prevent preeclampsia at 
the Mohammad Hoesin General Hospital in 
Palembang.
METHODS
This study was a randomized control trial 
conducted in Palembang (Fetomaternal polyclinic 
/ Department of Obstetrics and Gynecology Dr. 
Mohammad Hoesin Hospital) from June 2018 
to May 2019. The population of this study were 
all pregnant women who performed antenatal 
care in Palembang (Department / Obstetric 
Department and Gynecology Hospital Dr. 
Mohammad Hoesin). The inclusion criteria in this 
study were pregnant women aged 20 - 35 years, 
gestational age 20 weeks, pregnant women 
with blood pressure <140/90 mmHg, pregnant 
women with blood calcium before the study was 
low or normal, pregnant women did not suffer 
from chronic and metabolic diseases, willing 
to take part in research and sign an informed 
consent sheet. The exclusion criteria in this 
study were pregnant women with blood calcium 
before high research. This study used univariate 
data analysis to determine the frequency of 
occurrence of preeclampsia in each sample group. 
In addition, bivariate analysis was also conducted 
to determine the role of high-dose calcium 
in preventing preeclampsia by identifying the 
effect of high-dose calcium for pregnant women 
on the incidence of preeclampsia. The bivariate 
analysis was carried out using McNemar's test. 
The analysis in this study was carried out using 
the SPSS 16.0 assistance program.
Works Procedure
First thing fi rst, all women who meet the 
inclusion criteria were given an explanation of 
the research that will be conducted. Those who 
agreed to participate in this study were asked to 
sign informed consent that had been provided 
for the study, then all patients included in this 
study carried out recording complete patient data 
contained in the patient's medical records, then 
carried out anamnesis and physical examination 
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and laboratory support examinations (Hb, Ht and 
blood calcium). Blood collection was executed 
by phlebotomy, which was collected from the 
peripheral blood using a 5 mL syringe. Hematocrit 
and Hemoglobin were examined by a centrifuge 
technique using the electrical impedance method 
that was counting cells from whole blood and 
separating red blood cells and the returning 
elements of white blood cells (granulocytes, 
lymphocytes, and monocytes). 
Meanwhile, calcium was carried out by the 
cresolphtein complex one method. Next up, 
pregnant women are randomly put into two 
groups. From 20 weeks of gestation to 35 weeks 
were assigned to the high-dose calcium group or 
treatment group who received 1500 mg of oral 
calcium per day, and the low-dose calcium group 
or comparison group that received 500 mg of 
oral calcium per day. This study used a parallel 
approach which was used as a comparison to 
use low-dose calcium. Calcium supplementation 
given was elemental calcium (calcium carbonate) 
given 1500 mg/day (3 tablets of 500 mg Calos 
in one meal), given to the treatment group of 
pregnant women. Then, as a comparison, 3 
tablets were given to pregnant women, namely 
low-dose calcium supplementation which also 
used 500 mg of Calos / day (1 tablet of 500 mg 
Calos) and 1000 mg placebo (with the same size, 
weight, and colour as calcium carbonate) per day 
in one meal in the comparison group.
Accordingly, they were put into capsules of 
the same colour and different colour wrapping 
in each group. The next step, pregnant women 
were examined (follow-up) every 5 weeks 
until delivery. Supervision of compliance with 
calcium consumption in patients was done by 
contacting patients every week on the telephone 
and every 5 weeks face-to-face. Finally, blood 
pressure measurements were performed using 
a tool such as ABN Healthcare System® aneroid 
sphygmomanometer and Littman® Stethoscope.
RESULTS
Experimental analytical study with a Randomized 
Controlled Trial Single-blind design to determine 
the effectiveness of high doses of calcium in 
preventing preeclampsia has been carried out. 
The research sample that fulfi lled the inclusion 
and exclusion criteria was 34 people. A total of 17 
people received high-dose calcium and 17 others 
received low-dose calcium.
General Characteristics of Research
The average age of patients who received high 
calcium was 27.24 ± 2.86 years with a range of 20-
31 years while the average age for receiving low-
dose calcium was 27.94 ± 2.38 years with a range 
of 24-32 years. The statistical test showed that 
there was no age difference between patients 
who received high-dose calcium and low-dose 
calcium (p = 0.440). The average gestational 
age of patients who received high calcium was 
22.53 ± 2.07 weeks with a range of 20-25 weeks 
while the average gestational age who received 
low-dose calcium was 22.71 ± 2.08 weeks with a 
range of 20-27 weeks. The statistical test showed 
that there was no difference in gestational age 
between patients who received high-dose calcium 
and low-dose calcium (p = 0.888). Obstetric 
characteristics of patients receiving high calcium 
include gravida of 1.92 ± 0.89 with ranges from 
1-4, parity of 0.88 ± 0.86 with a range of 0-3 and 
an average incidence of abortion of 0.06 ± 0.24 
with a range of 0-1 while in patients who received 
calcium dose gravida was obtained at 2.29 ± 1.10 
with a range of 1-5, parity of 1.00 ± 1.12 with a 
range of 0-4 and a mean incidence of abortion of 
0.29 ± 0.59 with a range of 0-2. The statistical test 
showed that there were no gravida differences 
(p = 0.354), parity (p = 0.940) and abortion (p = 
0.145) between patients who received high-dose 
calcium and low-dose calcium and showed that 
the two groups were homogeneous.
In the distribution of labour in the study 
subjects, 58.8% of subjects gave birth 
spontaneously, 29.4% of subjects gave birth by 
section caesarean, and 11.8% of subjects who 
had not given birth in the high-dose calcium 
group, while there were as many as 52.9 % of 
subjects who gave birth spontaneously, 29.4% of 
subjects who gave birth by caesarean section and 
as many as 17.6% of subjects who had not given 
birth. From the analysis, there was no signifi cant 
relationship between labour and calcium groups.
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Table 1. General Characteristic of Research
Variable P-value*Calcium
High Dose Low Dose
Age
Mean ± SD
Median (Min-Max)
Gestational Age
Mean ± SD
Median (Min-Max)
Gravida
Mean ± SD
Median (Min-Max)
Parity
Mean ± SD
Median (Min-Max)
Abortion
Mean ± SD
Median (Min-Max)
Labor
Spontaneous
Sectio Caesarean
Have not given birth
27.23 ± 2.86
27 (20-31)
22.53 ± 2.07
22 (20-25)
1.94 ± 0.89
2 (1-4)
0.88 ± 0.86
1 (0-3)
0.06 ± 0.24
0 (0-1)
10
5
2
27.94 ± 2.38
28 (24-32)
22.71 ±2.08
22 (20-27)
2.29 ± 1.10
2 (1-5)
1.00 ± 1.12
1 (0-4)
0.29 ± 0.59
0 (0-2)
9
5
3
0.440a
0.888b
0.354b
0.940b
0.145b
0.881c
Table 2. Characteristics of Blood Pressure
Blood Pressure P-value*Calcium
High Dose Low Dose
First Visit
Mean ± SD (Sistolik)
Mean ± SD (Diastolic)
Second Visit
Mean ± SD (Sistolik)
Mean ± SD (Diastolic)
Third Visit
Mean ± SD (Sistolik)
Mean ± SD (Diastolic)
Fourth Visit
Mean ± SD (Sistolik)
Mean ± SD (Diastolic)
116.47±4.9
75.29±5.14
115.88±5.07
75.29±5.14
116.47±4.92
75.29±5.14
116.47±4.92
75.29±5.14
112.94±7.71
74.11±5.07
114.11±7.12
74.11±5.07
116.47±9.31
74.70±5.14
120.58±17.12
76.47±7.85
0.179
0.498
0.543
0.498
0.939
0.735
0.939
0.848
aIndependent T Test, p =0.05, bMann Whitney Test, p =0. 05, 
cFisher’s Exact Test, p =0.05
Independent T-test, p=0.05
Characteristics of Blood Pressure 
In this study, the research subjects visited 4 
times. The parameters examined included systolic 
and diastolic blood pressure. On the fi rst visit, it 
was found that the mean systolic and diastolic 
blood pressure was 116/75 mmHg in the high-
dose calcium group, and 112/74 mmHg in the 
low-dose calcium group. On the second visit, it 
was found that the mean systolic and diastolic 
blood pressure was 115/75 mmHg in the high-
dose calcium group, and 114/74 mmHg in the 
low-dose calcium group. On the third visit, the 
mean systolic and diastolic pressure was 116/75 
mmHg in the high-dose calcium group and 116/74 
mmHg. On the fourth visit, the mean systolic and 
diastolic blood pressure was 116/75 mmHg in 
the high-dose calcium group and 120/76 mmHg 
in low-dose calcium. From the analysis test, there 
were no meaningful differences in the two groups 
each visit.
In this study, it was also found that there 
were 17 subjects (100%) subjects who had blood 
pressure <140/90 at the fi rst visit to the fourth 
in the high-dose calcium group, whereas there 
were as many as 11 subjects (82.4%) who had 
blood pressure <140 / 90 on the fi rst to the 
fourth visit and 3 subjects (17.6%) who had blood 
pressure> 140/90 in the low dose calcium group 
on the third visit which was 150/110 and 160/120 
fourth visit.
Laboratory Characteristics of 
Research Subjects
In the distribution of hemoglobin levels for the 
calcium group, the mean haemoglobin level at 
the fi rst visit between the two groups was 12.32. 
On the second visit, the mean haemoglobin 
level between the two groups was 12.46 in the 
high calcium group and 12.36 in the low calcium 
group. On the third visit, the mean haemoglobin 
level between the two groups was 12.64 in the 
high calcium group and 12.50 in the low calcium 
group. At the last visit, the mean haemoglobin 
level between the two groups was 12.81 in the 
high calcium group and 12.61 in the low calcium 
group. With statistical analysis, it was found that 
there was no difference in haemoglobin levels at 
the fi rst visit (p = 1.000), second visit (p = 0.591), 
third visit (p = 0.392) and fourth visit (p = 0.279) 
between patients receiving high-dose calcium 
and low dose calcium.
In the distribution of hematocrit levels on the 
calcium group, the mean hematocrit levels at the 
fi rst visit between the two groups were 34.47 
in the high calcium group and 35.29 in the low 
calcium group, respectively. On the second visit, 
the mean hematocrit levels between the two 
groups were 34.47 in the high calcium group 
and 34.88 in the low calcium group. On the third 
visit, the mean hematocrit levels between the 
two groups were 34.76 in the high calcium group 
and 34.64 in the low calcium group. At the last 
visit, the mean hematocrit levels between the 
two groups were 35.17 in the high calcium group 
and 34.84 in the low calcium group. Based on 
statistical analysis it was found that there were no 
differences in hemoglobin levels at the fi rst visit 
(p = 0.254), second visit (p = 0.305), third visit 
(p = 0.707) and fourth visit (p = 0.531) between 
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Table 3. Average Hemoglobin Levels per Visit
Laboratory Characteristics
Hb First Visit
Mean ± SD
Median (Min-Max)
Hb Second Visit
Mean ± SD
Median (Min-Max)
Hb Third Visit
Mean ± SD
Median (Min-Max)
Hb Fourth Visit
Mean ± SD
Median (Min-Max)
Hematocrit First Visit
Mean ± SD
Median (Min-Max)
Hematocrit Second Visit
Mean ± SD
Median (Min-Max)
Hematocrit Third Visit
Mean ± SD
Median (Min-Max)
Hematocrit Fourth Visit
Mean ± SD
Median (Min-Max)
Calcium First Visit
Mean ± SD
Median (Min-Max)
Calcium Second Visit
Mean ± SD
Median (Min-Max)
Calcium Third Visit
Mean ± SD
Median (Min-Max)
Calcium Fourth Visit
Mean ± SD
Median (Min-Max)
12.32 ± 0.81
12.6 (11 – 13.5)
12.46 ± 0.67
12,5 (11,2 – 13.3)
12.50 ± 0.46
12.6 (11,5 – 13.5)
12.81 ± 0.42
12.8 (11.9 – 13.6)
3447 ± 2.50
35.0 (30.0 – 38.0)
34.47 ± 1.06
34.0 (33.0 – 36.0)
34.76 ± 0.97
35.0 (33,0 – 36.0)
35.17 ± 1.23
35,0 (34,0 – 38,0)
8.81 ± 0.59
8.7 (7.8 – 10.1)
9.26 ± 0.59
9.2 (8.2 – 10.6)
9.56 ± 0,56
9.5 (8.7 – 10.8)
10.1 ± 0.69
10 (9.1 – 11.2)
12.32 ± 0.44
12.4(11.3 – 13.0)
12.36 ± 0.35
12.4 (11.5 – 12.8)
12.50 ± 0.47
12.6 (11.5 – 13.1)
12.61 ± 0.64
12.7 (11.1 – 13.4)
35.29 ± 1.49
35.0 (33.0 – 38.0)
34.88 ± 1.05
35.0 (33.0 – 37.0)
34.64 ± 1.41
35.0 (32.0 – 38.0)
34.94 ± 1.39
35,0 (33.0 – 37.0)
8.68 ± 0.49
8.7 (7.8 – 9.9)
9,00 ± 0,41
8.9 (8.2 – 9.6)
9.35 ± 0.47
9.4 (8.4 – 10.2)
10.1 ± 1.04
9.8 (8.8 – 12.8)
1.000a
0.591a
0.392a
0.279a
0.254a
0.305b
0.707b
0.531b
0.512a
0.888a
0.151a
0.809b
P-value*Calcium 
Low DoseHigh Dose
Independent T-test, p=0.05a, Mann-Whitney, p=0.05b
patients who received high-dose calcium and low 
dose calcium.
In the distribution of Calcium levels against 
the calcium group, the mean calcium levels at 
the fi rst visit between the two groups were 8.81 
and 8.68, respectively. On the second visit, the 
average calcium level between the two groups 
was 9.26 in the high calcium group and 9.00 in 
the low calcium group. On the third visit, the 
Comparison of the Effectiveness of High and 
Low Calcium Doses
In this study, after high calcium intervention, no 
pregnant women with preeclampsia were found, 
whereas in the low-dose calcium intervention 
group it was found that 3 of 17 patients (17.7%) 
had preeclampsia. With the McNemar test, it 
was found that there was no difference in the 
average calcium level between the two groups 
was 9.56 in the high calcium group and 9.35 in the 
low calcium group. At the last visit, the average 
calcium level of each group was 10.1. Based on 
calcium levels, there was no difference in calcium 
levels at visit-1 (p = 0.512), visit-2 (p = 0.151), 
visit-3 (p = 0.256) and visit-4 (p = 0.809) between 
patients who got high-dose calcium and low-
dose calcium.
incidence of preeclampsia both after high-dose 
calcium and low-dose calcium interventions (p 
= 0.250). This means high and low calcium is 
effective for preventing preeclampsia.
DISCUSSION
The increasing incidence of preeclampsia in 
pregnant women is caused by various factors. 
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Risk factors that can increase the incidence of 
preeclampsia are hydatidiform mole, nulliparous, 
age less than 20 years or more than 35 years, more 
than one fetus, multiparas, chronic hypertension, 
diabetes mellitus or kidney disease. Preeclampsia 
is also infl uenced by parity, genetics and 
environmental factors.3
WHO (2013) states that the administration 
of calcium to pregnant women is one way that 
can be used to prevent preeclampsia. A review 
of 24 studies found that high doses of calcium 
supplementation (at least 1 g a day) during 
pregnancy from 13 studies involving 15,730 
women were a safe and relatively inexpensive way 
to reduce the risk of preeclampsia, especially in 
women with low calcium diets who had increased 
risk preeclampsia. Women who receive calcium 
supplements also reduce their risk of dying 
or experiencing serious problems related to 
preeclampsia. Premature birth rates also dropped. 
The use of calcium supplements in pregnant 
women has no side effects. WHO recommends 
giving calcium to pregnant women by 1.5 g to 2 
g every day for pregnant women who have low 
calcium intake. But several other studies suggest 
that administration of low doses of calcium can 
signifi cantly reduce the risk of preeclampsia, 
reduce hypertension and reduce the number of 
babies with low birth weight babies.2,7
The average age of patients who received high 
calcium was 27.24 ± 2.86 years with a range of 20-
31 years while the average age for receiving low-
dose calcium was 27.94 ± 2.38 years with a range 
of 24-32 years. The average research subject he 
got was 27 years old, while the average age of 
the research subjects Crowther did was aged 24-
25 years. This can be different because the study 
population is not the same. In addition to age, 
work and education level can affect the incidence 
of preeclampsia. Low-educated women were 
86% more at risk of preeclampsia, while women 
with secondary education were 72% more at risk 
of preeclampsia, but the level of education might 
be a stressor in making decisions. Work was not 
related to the prevalence of preeclampsia in his 
study.8-11
The average gestational age of patients who 
received high calcium was 22.53 ± 2.07 weeks 
with a range of 20-25 weeks while the average 
gestational age who received low-dose calcium 
was 22.71 ± 2.08 weeks with a range of 20-27 
weeks. The average gestational age for receiving 
calcium is 20 weeks' gestation, while the average 
gestational age in the Levine study is a 17-week 
gestational age range. The WHO recommends 
that calcium supplements be started for pregnant 
women at 20 weeks' gestation, based on the 
reference time used in the WHO meta-analysis. 
The mechanism of action of these calcium 
supplements postulates involving modulation 
of both placental vascularization and systemic 
vasomotor activity. Although this postulation 
has not been directly tested, it shows that 
periconceptional calcium supplementation may 
be more benefi cial, and initiation from the age of 
20 weeks of pregnancy.2,12-14
Obstetric characteristics of patients receiving 
high calcium include gravida of 1.92 ± 0.89 with 
ranges from 1-4, parity of 0.88 ± 0.86 with a range 
of 0-3 and an average incidence of abortion of 
0.06 ± 0.24 with a range of 0-1 while in patients 
who received calcium dose gravida was obtained 
at 2.29 ± 1.10 with a range of 1-5, parity of 1.00 
± 1.12 with a range of 0-4 and a mean incidence 
of abortion of 0.29 ± 0.59 with a range of 0-2. 
The statistical test showed that there were no 
gravida differences (p = 0.354), parity (p = 0.940) 
and abortion (p = 0.145) between patients 
who received high-dose calcium and low-dose 
calcium and showed that the two groups were 
homogeneous.
In the distribution of subjects to the calcium 
group, at the fi rst visit, it was found that the 
mean systolic and diastolic blood pressure was 
116/75 mmHg in the high-dose calcium group, 
and 112/74 mmHg in the low-dose calcium 
group. On the second visit, it was found that the 
mean systolic and diastolic blood pressure was 
115/75 mmHg in the high-dose calcium group, 
and 114/74 mmHg in the low-dose calcium 
group. On the third visit, the mean systolic and 
diastolic pressure was 116/75 mmHg in the high-
dose calcium group and 116/74 mmHg. On the 
fourth visit, the mean systolic and diastolic blood 
pressure was 116/75 mmHg in the high-dose 
calcium group and 120/76 mmHg in low-dose 
calcium. From the analysis test, there were no 
meaningful differences in the two groups each 
visit. In this study, it was also found that there 
were 17 subjects (100%) subjects who had blood 
pressure <140/90 at the fi rst visit to the fourth in 
the high-dose calcium group, whereas there were 
as many as 11 subjects (82.4%) who had blood 
pressure <140 / 90 on the fi rst to fourth visits 
and 3 subjects (17.6%) who had blood pressure> 
140/90 in the low-dose calcium group on the 
third and fourth visits.
There were very few samples who 
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experienced hypertension by consuming calcium 
supplementation (10 trials, 6634 women, RR 0.81, 
95% CI: 0.74 - 0.89), but there were variations in 
the magnitude of effects across subgroups. The 
RR channel plot of sample size shows asymmetric 
plots, with a smaller effect in trials greater than 
1000 subjects. The magnitude of the effect is far 
greater among women who are at high risk of 
hypertension (4 trials, 327 women, RR 0.45, 95% 
CI: 0.31 - 0.66), and those with low initial dietary 
calcium (5 trials, 1582 women; RR 0.49, 95% CI: 
0.38 - 0.62).15
In the distribution of labour in the study 
subjects, 58.8% of subjects gave birth 
spontaneously, 29.4% of subjects gave birth by 
cesarean section, and 11.8% of subjects who 
had not given birth in the high-dose calcium 
group, while there were as many as 52.9 % of 
subjects who gave birth spontaneously, 29.4% of 
subjects who gave birth by cesarean section and 
as many as 17.6% of subjects who had not given 
birth. From the analysis, there was no signifi cant 
relationship between labour and calcium groups. 
There was no signifi cant difference between the 
types of labour in the calcium group.15
The type of labour in cases of preeclampsia 
found that there were 172 with vaginal deliveries 
and 21 with planned cesarean delivery. Moreover, 
women with cesarean delivery after a long period 
had a 10-fold higher risk of maternal outcomes 
compared with women with planned cesarean 
delivery (adjusted odds ratio (AOR) 9.7 (1.2 to 
78.6), P = 0.03) or with vaginal delivery ≤ 24 
hours (a OR 9.7 (1.4 to 67.4), P = 0.02).12,16
From the independent t-test analysis it was 
found that there was no signifi cant difference in 
the mean hemoglobin at each visit with a value of 
p = 1,000; p = 0.591; p = 0.392; p = 0.279. Calcium 
acts as an inhibitor of iron or iron absorption 
used to synthesize hemoglobin, but in the study, 
it was found that there was no decrease in the 
administration of both high and low doses of 
calcium. Anne Marie said that there were no 
changes in the hematological index, including 
hemoglobin, hematocrit, zinc protoporphyrin, 
and plasma ferritin produced from calcium 
supplementation. Anne added that long-term 
supplementation with calcium does not reduce 
plasma ferritin concentrations in adults who are 
still actively consuming iron-containing foods. 
High hemoglobin concentrations in the fi rst 
trimester showed risk factors for pregnancy-
induced hypertension (OR = 2,462; 95% CI, 
1-6,9). But this cannot be proven in this study. 
Hemoglobin Hemoglobin levels in the fi rst and 
second trimesters were associated with adverse 
pregnancy outcomes such as preeclampsia. 
An increase in hemoglobin concentration is a 
vasoconstriction cause in preeclampsia.15-19
From the independent t-test analysis it was 
found that there was no signifi cant difference 
in hematocrit on each visit with a value of p = 
0.254; p = 0.305; p = 0.707; p = 0.531. There were 
no differences in hematocrit between high-dose 
calcium and low-dose calcium. There was no 
signifi cant difference between hematocrit levels 
in severe preeclampsia both before labour and 
after delivery with a value of p> 0.05.17-21
From the independent t-test analysis, it was 
found that there was no signifi cant difference in 
the mean calcium for each visit with a value of 
p = 0.512; p = 0.151; p = 0.256; p = 0.809. From 
the McNemar test, it was found that there was no 
difference in the incidence of preeclampsia both 
after high-dose calcium interventions and low-
dose calcium (p = 0.250). This means high and low 
calcium is effective for preventing preeclampsia. 
Calcium supplementation during pregnancy 
was associated with a signifi cant 45% reduction 
in the risk of gestational hypertension [Relative 
risk (RR) 0.55; 95% confi dence interval (CI) 0.36-
0.85] and 59% in the risk of preeclampsia [RR 
0.41; 95% CI 0.24-0.69] in developing countries. 
Calcium supplementation during pregnancy was 
also associated with a signifi cant reduction in 
neonatal mortality [RR 0.70; 95% CI 0.56-0.88] 
and the risk of preterm birth [RR 0.88, 95% CI 
0.78-0.99]. Recommendations for LST to reduce 
maternal mortality are based on a reduction in 
the risk of gestational hypertension related to 
severe morbidity/mortality [RR 0.80; 95% CI 
0.70-0.91] and for neonatal deaths based on 
reduced risk for all causes of neonatal death [RR 
0.70; 95% CI 0.56-0.88]. Whereas, who examined 
calcium administration in cases of recurrent 
preeclampsia said that there was no signifi cant 
decrease in recurrent preeclampsia with calcium 
supplementation before and during early 
pregnancy. This experiment is fundamentally 
different from previous calcium trials to prevent 
pre-eclampsia.15,22
Calcium is a nutrient that must be consumed in 
suffi cient proportion in food to ensure adequate 
serum levels because it is not produced in the 
body. In pregnancy, serum calcium levels tend 
to decrease because active transport crosses the 
placenta to the fetus, which can accumulate up 
to 25-30 g during pregnancy, especially in the 
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third trimester. In pregnancy, the absorption of 
calcium from the digestive tract also increases, 
mainly because of an increase in 1,25-dihydroxy 
vitamin D levels and increased urinary calcium 
excretion. Parathyroid hormone and calcitonin 
levels increase which subsequently impacts on 
serum calcium levels. Calcium intake needed 
in pregnancy is 1000 mg per day, however, 
it is recommended that only 6% of pregnant 
women reach this daily amount. The maternal 
risk of calcium defi ciency in pregnancy includes 
osteopenia, osteoporosis, tremor, paresthesia, 
muscle cramps and tetany. Calcium also has a role 
in fetal bone mineralization and in preventing 
fetal growth restriction. Serum calcium levels 
have been found to be reduced in patients with 
preeclampsia and calcium defi ciency that is 
also associated with other pregnancy morbidity 
such as preterm labor. Potential pathological 
mechanisms behind calcium defi ciency and 
potential preeclampsia through parathyroid 
hormone and renin release, increase intracellular 
calcium levels and lead to vasoconstriction 
through contraction of smooth muscle blood 
vessels.20-23
The limitations of this study are limited sample 
size and research time. In addition, this study only 
compared the administration of high doses of 
calcium and low doses without knowing whether 
there were other calcium intake such as milk for 
pregnant women used by the research subjects. 
However, the basic data from this study can be 
used as data for further research.
CONCLUSION
The administration of high-dose calcium, in this 
study used calcium carbonate in accordance with 
WHO recommendations (1.5-2 g), effective in 
preventing the occurrence of severe preeclampsia 
and there was no difference in effectiveness 
between administration of high-dose calcium 
with low-dose calcium administration to the 
incidence of preeclampsia with a value of p = 
0.250.
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